GNPX Genprex, Inc. stock chart & analysis
Conviction 49HealthcareScan · Fri, Nov 6, 2026Genprex, Inc. (GNPX) closed at $2.07 (-1.43%) on Nov 6, 2026. Price is below its 50-day and below its 200-day moving average. RSI(14) 38, RS Rating 1, -97.9% from its 52-week high, -92.5% year to date. Sector: Healthcare · Pharmaceutical Preparations.
Financials as of Tue, Jun 30, 2026 · quarterly.
GNPX technical analysis
Trend
GNPX is in a downtrend: price is below the 50-day, which is below the 200-day moving average. It closed 25.2% below the 50-day ($2.80) and 85.2% below the 200-day ($14.13). ADX(14) at 21 points to a moderate trend. It meets 0 of 8 trend-template criteria.
Momentum
RSI(14) is 38, in the bearish half of its range. MACD crossed above its signal line 7 sessions ago. Its RS Rating of 1 puts its weighted 12-month performance ahead of about 1% of the US market.
Volume and volatility
Volume on the latest session ran 0.4× its 20-day average. It trades about $415,660 a day on average. ATR(14) is $0.2249, 10.8% of price — its typical daily range. On-balance volume is trending down. Chaikin Money Flow (-0.27) shows distribution.
Key levels
The chart pattern's support is $2.12 and its resistance $3.57. The 52-week range is $1.71 to $100.80; price is 97.9% below the high and 22.2% above the low. The VWAP anchored at the 52-week high is $11.11, above price.
Performance
GNPX returned -6.7% (1 week), -24.0% (1 month), -50.1% (3 months), -85.0% (6 months), -97.8% (1 year), -92.5% (year to date).
About Genprex, Inc.
Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Gene Therapy (quaratusugene ozeplasmid), is initially being developed in combination with prominent, approved cancer drugs to treat Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC).
Pharmaceutical Preparations · Listed 2018 · 13 employees
Recent news
- Genprex, Inc.: Material event (8-K)SEC EDGAR · Wed, Nov 4, 2026
Congress activity
Disclosed STOCK Act trades in GNPX · 1 recent
| Member | Side | Amount | Traded | Filed | PTR |
|---|---|---|---|---|---|
 Tim Moore house · NC · traded 2025-12-18 | Buy | $1K–$15K | 2025-12-18 | 2026-01-03 |
Insider activity
SEC Form 4 transactions in GNPX · open-market 2 sells
| Insider | Side | Shares | Value | Traded | Filed |
|---|---|---|---|---|---|
LONGNECKER BRENT M Director · Common Stock · 2026-04-14 | Sell | 10 | $12 | 2026-04-14 | 2026-04-15 |
LONGNECKER BRENT M Director · Common Stock · 2026-04-14 | Sell | 8 | $10 | 2026-04-14 | 2026-04-15 |
SEC filings
EDGAR filings in GNPX · 10 recent
Get daily signals & real-time alerts.
StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 7 days, no credit card.
Start free — 7-day trial, no card →Free daily signals by email. Top 3 setups per lane after every close. No account needed.
Unsubscribe anytime · Privacy
Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.